/KYTX
KYTX Stock - Kyverna Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$7.19+2.71%
+$0.19 (+2.71%) • Dec 19
64
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.75
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+297.8%upside
Target: $28.60
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for KYTX
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$7.12 – $7.26
TARGET (TP)$28.60
STOP LOSS$6.61
RISK/REWARD1:36.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.69
52W High$13.67
52W Low$1.78
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | N/A | N/A | $7.03M | $5.66M |
| Gross Profit | $-2,133,000 | $-1,707,000 | $7.03M | $5.66M |
| Gross Margin | N/A | N/A | 100.0% | 100.0% |
| Operating Income | $-142,604,000 | $-62,406,000 | $-29,384,000 | $-26,346,000 |
| Net Income | $-127,477,000 | $-60,366,000 | $-28,893,000 | $-26,350,000 |
| Net Margin | N/A | N/A | -411.3% | -465.9% |
| EPS | $-3.33 | $-0.00 | $-1.12 | $-1.02 |
Company Overview
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
83%
Hold / Neutral
1
17%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$27
Average Target
↑ 270.3% Upside
Now
$5
Low
$27
Average
$48
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| August 20th 2025 | William Blair | Initiation | Outperform | - |
| May 27th 2025 | H.C. Wainwright | Upgrade | Buy | $5 |
| October 10th 2024 | UBS | Initiation | Buy | $13 |
| October 9th 2024 | Rodman & Renshaw | Initiation | Buy | $16 |
| July 3rd 2024 | H.C. Wainwright | Initiation | Neutral | $8 |
| March 4th 2024 | Morgan Stanley | Initiation | Overweight | $40 |
| March 4th 2024 | JP Morgan | Initiation | Overweight | $39 |
| March 4th 2024 | Wells Fargo | Initiation | Overweight | $44 |
| March 4th 2024 | Leerink Partners | Initiation | Outperform | $48 |
Earnings History & Surprises
KYTXBeat Rate
50%
Last 8 quarters
Avg Surprise
-91.2%
EPS vs Estimate
Beats / Misses
4/4
Last 12 quarters
Latest EPS
$-0.85
Q4 2025
EPS Surprise History
Q1 24
-731.6%
$-26.86vs$-3.23
Q2 24
-27.3%
$-1.12vs$-0.88
Q3 24
+4.3%
$-0.67vs$-0.70
Q4 24
-3.9%
$-0.80vs$-0.77
Q1 25
-1.1%
$-0.88vs$-0.87
Q2 25
+14.9%
$-1.03vs$-1.21
Q3 25
+3.0%
$-0.97vs$-1.00
Q4 25
+12.4%
$-0.85vs$-0.97
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | $-0.84 | — | — | — |
Q4 2025 | Nov 12, 2025 | $-0.97 | $-0.85 | +12.4% | ✓ BEAT |
Q3 2025 | Aug 12, 2025 | $-1.00 | $-0.97 | +3.0% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-1.21 | $-1.03 | +14.9% | ✓ BEAT |
Q1 2025 | Mar 27, 2025 | $-0.87 | $-0.88 | -1.1% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.77 | $-0.80 | -3.9% | ✗ MISS |
Q3 2024 | Aug 12, 2024 | $-0.70 | $-0.67 | +4.3% | ✓ BEAT |
Q2 2024 | May 14, 2024 | $-0.88 | $-1.12 | -27.3% | ✗ MISS |
Q1 2024 | Feb 8, 2024 | $-3.23 | $-26.86 | -731.6% | ✗ MISS |
Q3 2023 | Sep 30, 2023 | — | $-0.36 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.30 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.43 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.20 | — | — |
Latest News
Kyverna Therapeutics shares are trading lower after the company announced $100 million public offering of approximately 13.334 million shares at $7.50 per share.
📉 NegativeBenzinga•Dec 17, 2025, 04:10 PM
Kyverna Therapeutics Announces ~$100M Public Offering Of ~13.334M Shares At A Price Of $7.50/Share
➖ NeutralBenzinga•Dec 17, 2025, 02:27 PM
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $33
📈 PositiveBenzinga•Dec 16, 2025, 02:57 PM
Kyverna Therapeutics shares are trading lower after the company announced a $100 million offering.
📉 NegativeBenzinga•Dec 15, 2025, 09:02 PM
Kyverna Therapeutics Announces $100M Proposed Public Offering
➖ NeutralBenzinga•Dec 15, 2025, 09:01 PM
Kyverna Therapeutics shares are trading higher after the company announced topline data from KYSA-8.
📈 PositiveBenzinga•Dec 15, 2025, 02:25 PM
Market-Moving News for December 15th
➖ NeutralBenzinga•Dec 15, 2025, 12:26 PM•Also:
Kyverna Therapeutics Released Topline Data From KYSA-8 Phase 2 Trial Of Mivocabtagene Autoleucel For Stiff Person Syndrome, Miv-Cel Achieved Statistically Significant Clinical Benefit Across All Primary And Secondary Endpoints
📈 PositiveBenzinga•Dec 15, 2025, 11:33 AM
Reported Sunday, Kyverna Prepares To Announce Topline Registrational Phase 2 Data For KYV-101 In Stiff Person Syndrome
➖ NeutralBenzinga•Dec 15, 2025, 07:24 AM
Morgan Stanley Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $25
📈 PositiveBenzinga•Dec 4, 2025, 06:05 PM
Kyverna Therapeutics Q3 EPS $(0.85) Beats $(0.92) Estimate
📈 PositiveBenzinga•Nov 12, 2025, 09:47 PM
Kyverna Therapeutics Closes Loan Facility Up To $150M In Non-Dilutive Capital With Oxford Finance
📈 PositiveBenzinga•Nov 3, 2025, 01:09 PM
Wells Fargo Maintains Overweight on Kyverna Therapeutics, Raises Price Target to $31
📈 PositiveBenzinga•Oct 30, 2025, 02:35 PM
KYTX stock has given up its prior gain. Kyverna Therapeutics shares were trading higher after the company announced interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis.
➖ NeutralBenzinga•Oct 29, 2025, 01:55 PM
Kyverna Therapeutics shares are trading higher after the company announced interim data from the Phase 2 portion of the registrational KYSA-6 clinical trial of KYV-101 in generalized myasthenia gravis.
📈 PositiveBenzinga•Oct 29, 2025, 01:04 PM
Kyverna Therapeutics Announces Interim Phase 2 Data From KYSA-6 Study Of KYV-101 In Generalized Myasthenia Gravis At AANEM 2025; 100% Of Patients Achieved Clinically Meaningful Responses In MG-ADL And QMG, The Co-Primary Endpoints Of The Phase 3 Trial.
📈 PositiveBenzinga•Oct 29, 2025, 10:36 AM
HC Wainwright & Co. Maintains Buy on Kyverna Therapeutics, Raises Price Target to $20
📈 PositiveBenzinga•Oct 27, 2025, 11:06 AM
Reported Saturday, Kyverna Therapeutics Highlights Phase 1 Data Showing KYV-101 Drives Profound Reduction In Autoantibodies In Refractory Rheumatoid Arthritis
📈 PositiveBenzinga•Oct 27, 2025, 06:54 AM
Kyverna Therapeutics To Discuss Interim Data From KYSA-6 Phase 2 Clinical Study Evaluating KYV-101 In Generalized Myasthenia Gravis On Oct. 29
➖ NeutralBenzinga•Oct 22, 2025, 12:03 PM
Kyverna Therapeutics shares are trading higher after Wells Fargo maintained its Overweight rating and raised the price target on the stock from $24 to $27.
📈 PositiveBenzinga•Oct 8, 2025, 02:52 PM
Frequently Asked Questions about KYTX
What is KYTX's current stock price?
Kyverna Therapeutics, Inc. (KYTX) is currently trading at $7.19 per share. The stock has moved +2.71% today.
What is the analyst price target for KYTX?
The average analyst price target for KYTX is $28.60, based on 1 analyst.
What sector is Kyverna Therapeutics, Inc. in?
Kyverna Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is KYTX's market cap?
Kyverna Therapeutics, Inc. has a market capitalization of $0.31 billion, making it a small-cap company.
Does KYTX pay dividends?
No, Kyverna Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALLO
Allogene Therapeutics, Inc.
$1.42
Mkt Cap: $0.3B
AVIR
Atea Pharmaceuticals, Inc.
$3.14
Mkt Cap: $0.2B
CABA
Cabaletta Bio, Inc.
$2.39
Mkt Cap: $0.2B
CAPR
Capricor Therapeutics, Inc.
$27.81
Mkt Cap: $1.3B
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
$11.74
Mkt Cap: $0.3B
EDIT
Editas Medicine, Inc.
$2.34
Mkt Cap: $0.2B
LXEO
Lexeo Therapeutics, Inc. Common Stock
$10.35
Mkt Cap: $0.8B
LYEL
Lyell Immunopharma, Inc.
$33.33
Mkt Cap: $0.7B
MREO
Mereo BioPharma Group plc
$2.00
Mkt Cap: $0.3B
SLN
Silence Therapeutics plc
$6.37
Mkt Cap: $0.3B
Explore stocks similar to KYTX for comparison